Intolerance to statins: Mechanisms and management

Diabetes Care

Volumn 36, Issue SUPPL.2, 2013, Pages

  Bitzur, Rafael ^a   Cohen, Hofit ^a   Kamari, Yehuda ^a   Harats, Dror ^a  

^a SHEBA MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ATORVASTATIN; BILE ACID SEQUESTRANT; CALCIUM ION; CERIVASTATIN; CHOLESTEROL; COLESEVELAM; CREATINE KINASE; EZETIMIBE; FLUINDOSTATIN; GLUCOCORTICOID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MITOCHONDRIAL DNA; NICOTINIC ACID; PLACEBO; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; SOLUTE CARRIER ORGANIC ANION TRANSPORTER 1B1; UBIDECARENONE;

AGE; ARTHRALGIA; ARTHRITIS; ARTICLE; BRAIN HEMORRHAGE; CALCIUM CELL LEVEL; CALCIUM SIGNALING; CATARACT; CLINICAL EVALUATION; COGNITIVE DEFECT; DIABETES MELLITUS; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG BLOOD LEVEL; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENZYME INHIBITION; GASTROINTESTINAL SYMPTOM; GENE MUTATION; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; HEREDITY; HIGH RISK PATIENT; HOT FLUSH; HUMAN; IMMUNE MYOPATHY; IMMUNOSUPPRESSIVE TREATMENT; INSOMNIA; LIVER TOXICITY; LOW DRUG DOSE; MUSCLE FIBER MEMBRANE; MYALGIA; MYOPATHY; MYOSITIS; NONHUMAN; NONINFLAMMATORY MYOPATHY; PATHOGENESIS; PATIENT COMPLIANCE; PATIENT IDENTIFICATION; PERIPHERAL NEUROPATHY; RHABDOMYOLYSIS; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; SKELETAL MUSCLE; SLCO1B1 GENE; STATIN INDUCED MYOPATHY; TENDINITIS; TOXIC MYOPATHY; UNSPECIFIED SIDE EFFECT;

CARDIOVASCULAR DISEASES; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; IMMUNE SYSTEM; MITOCHONDRIA, MUSCLE; MUSCULAR DISEASES;

EID: 84891804222     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dcS13-2038     Document Type: Article

References (46)

1. Shalev V, Chodick G, Silber H, Kokia E, Jan J, Heymann AD. Continuation of statin treatment and all-cause mortality: a population-based cohort study. Arch Intern Med 2009;169:260-268
2. Chodick G, Shalev V, Gerber Y, et al. Long-term persistence with statin treatment in a not-for-profit health maintenance organization: a population-based retrospective cohort study in Israel. Clin Ther 2008;30:2167-2179
3. Bays H. Statin safety: an overview and assessment of the datad2005. Am J Car-diol 2006;97:6C-26C
4. Bruckert E, Hayem G, Dejager S, Yau C, Bégaud B. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patientsdthe PRIMO study. Cardiovasc Drugs Ther 2005;19:403-414
5. Buettner C, Rippberger MJ, Smith JK, Leveille SG, Davis RB, Mittleman MA. Statin use and musculoskeletal pain among adults with and without arthritis. Am J Med 2012;125:176-182
6. Mancini GB, Baker S, Bergeron J, et al. Diagnosis, prevention, and management of statin adverse effects and intolerance: proceedings of a Canadian Working Group Consensus Conference. Can J Cardiol 2011;27:635-662
7. Thompson PD, Clarkson PM, Rosenson RS; National Lipid Association Statin Safety Task Force Muscle Safety Expert Panel. An assessment of statin safety by muscle experts. Am J Cardiol 2006;97: 69C-76C
8. Link E, Parish S, Armitage J, et al.; SEARCH Collaborative Group. SLCO1B1 variants and statin-induced myopathyd a genomewide study. N Engl J Med 2008;359:789-799
9. Santos PC, Gagliardi AC, Miname MH, et al. SLCO1B1 haplotypes are not associated with atorvastatin-induced myalgia in Brazilian patients with familial hypercholesterolemia. Eur J Clin Pharmacol 2012;68:273-279
10. Neuvonen PJ, Niemi M, Backman JT. Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin Pharmacol Ther 2006;80:565-581
11. Knauer MJ, Urquhart BL, Meyer zu Schwabedissen HE, et al. Human skeletal muscle drug transporters determine local exposure and toxicity of statins. Circ Res 2010;106:297-306
12. Sirtori CR, Mombelli G, Triolo M, Laaksonen R. Clinical response to statins: mechanism(s) of variable activity and adverse effects. Ann Med 2012;44:419-432
13. Mammen AL, Amato AA. Statin myopathy: a review of recent progress. Curr Opin Rheumatol 2010;22:644-650
14. Vladutiu GD, Simmons Z, Isackson PJ, et al. Genetic risk factors associated with lipid-lowering drug-induced myopathies. Muscle Nerve 2006;34:153-162
15. Phillips PS, Haas RH, Bannykh S, et al.; Scripps Mercy Clinical Research Center. Statin-associated myopathy with normal creatine kinase levels. Ann Intern Med 2002;137:581-585
16. Schick BA, Laaksonen R, Frohlich JJ, et al. Decreased skeletal muscle mitochondrial DNA in patients treated with high-dose simvastatin. Clin Pharmacol Ther 2007; 81:650-653
17. Lamperti C, Naini AB, Lucchini V, et al. Muscle coenzyme Q10 level in statin-related myopathy. Arch Neurol 2005;62: 1709-1712
18. Marcoff L, Thompson PD. The role of coenzyme Q10 in statin-associated myopathy: a systematic review. J Am Coll Cardiol 2007;49:2231-2237
19. Laaksonen R, Jokelainen K, Laakso J, et al. The effect of simvastatin treatment on natural antioxidants in low-density lipoproteins and high-energy phosphates and ubiquinone in skeletal muscle. Am J Cardiol 1996;77:851-854
20. Bouitbir J, Charles AL, Echaniz-Laguna A, et al. Opposite effects of statins on mitochondria of cardiac and skeletal muscles: a 'mitohormesis' mechanism involving reactive oxygen species and PGC-1. Eur Heart J 2012;33:1397-1407
21. Schaars CF, Stalenhoef AF. Effects of ubiquinone (coenzyme Q10) on myopathy in statin users. Curr Opin Lipidol 2008;19:553-557
22. Young JM, Florkowski CM, Molyneux SL, et al. Effect of coenzyme Q(10) supplementation on simvastatin-induced myalgia. Am J Cardiol 2007;100:1400-1403
23. Caso G, Kelly P, McNurlan MA, Lawson WE. Effect of coenzyme q10 on myopathic symptoms in patients treated with statins. Am J Cardiol 2007;99:1409-1412
24. Sirvent P, Mercier J, Lacampagne A. New insights into mechanisms of statin-associated myotoxicity. Curr Opin Pharmacol 2008; 8:333-338
25. Araki M, Maeda M, Motojima K. Hydro-phobic statins induce autophagy and cell death in human rhabdomyosarcoma cells by depleting geranylgeranyl diphosphate. Eur J Pharmacol 2012;674:95-103
26. Flint OP, Masters BA, Gregg RE, Durham SK. Inhibition of cholesterol synthesis by squalene synthase inhibitors does not induce myotoxicity in vitro. Toxicol Appl Pharmacol 1997;145:91-98
27. Nishimoto T, Tozawa R, Amano Y, Wada T, Imura Y, Sugiyama Y. Comparing myotoxic effects of squalene synthase inhibitor, T-91485, and 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors in human my-ocytes. Biochem Pharmacol 2003;66: 2133-2139
28. Westwood FR, Bigley A, Randall K, Marsden AM, Scott RC. Statin-induced muscle necrosis in the rat: distribution, development, and fibre selectivity. Tox-icol Pathol 2005;33:246-257
29. Pierno S, De Luca A, Tricarico D, et al. Potential risk of myopathy by HMG-CoA reductase inhibitors: a comparison of pravastatin and simvastatin effects on membrane electrical properties of rat skeletal muscle fibers. J Pharmacol Exp Ther 1995;275:1490-1496
30. Schalke BB, Schmidt B, Toyka K, Hartung HP. Pravastatin-associated inflammatory myopathy. N Engl J Med 1992;327:649-650
31. Grable-Esposito P, Katzberg HD, Greenberg SA, Srinivasan J, Katz J, Amato AA. Immune-mediated necrotizing myopathy associated with statins. Muscle Nerve 2010;41:185-190
32. Needham M, Fabian V, Knezevic W, Panegyres P, Zilko P, Mastaglia FL. Progressive myopathy with up-regulation of MHC-I associated with statin therapy. Neuromuscul Disord 2007;17:194-200
33. Mammen AL, Chung T, Christopher-Stine L, et al. Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase in patients with statin-associated autoimmune myopathy. Arthritis Rheum 2011;63:713-721
34. Baigent C, Blackwell L, Emberson J, et al.; Cholesterol Treatment Trialists' (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170, 000 participants in 26 randomised trials. Lancet 2010;376:1670-1681
35. Lee P, Greenfield JR, Campbell LV, Vitamin D insufficiency-a novel mechanism of statin-induced myalgia? Clin Endo-crinol (Oxf) 2009;71:154-155
36. Law M. Plant sterol and stanol margarines and health. BMJ 2000;320:861-864
37. Hansen KE, Hildebrand JP, Ferguson EE, Stein JH. Outcomes in 45 patients with statin-associated myopathy. Arch Intern Med 2005;165:2671-2676
38. Stein EA, Ballantyne CM, Windler E, et al. Efficacy and tolerability of fluvastatin XL 80 mg alone, ezetimibe alone, and the combination of fluvastatin XL 80 mg with ezetimibe in patients with a history of muscle-related side effects with other statins. Am J Cardiol 2008;101:490-496
39. Backes JM, Venero CV, Gibson CA, et al. Effectiveness and tolerability of every-other-day rosuvastatin dosing in patients with prior statin intolerance. Ann Phar-macother 2008;42:341-346
40. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA 1984;251:351-364
41. Zema MJ. Colesevelam HCl and ezetimibe combination therapy provides effective lipid-lowering in difficult-to-treat patients with hypercholesterolemia. Am J Ther 2005;12:306-310
42. Insull W Jr. Clinical utility of bile acid sequestrants in the treatment of dyslipidemia: a scientific review. South Med J 2006; 99:257-273
43. Berge KG, Canner PL; Coronary Drug Project Research Group. Coronary drug project: experience with niacin. Eur J Clin Pharmacol 1991;40(Suppl 1):S49-S51
44. AIM-HIGH Investigators. Boden WE, Probstfield JL, Anderson T, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 2011;365:2255-2267
45. Thompson GR; HEART-UK LDL Apher-esis Working Group. Recommendations for the use of LDL apheresis. Atherosclerosis 2008;198:247-255
46. Stein EA, Bays H, O'Brien D, Pedicano J, Piper E, Spezzi A. Lapaquistat acetate: development of a squalene synthase inhibitor for the treatment of hypercholesterolemia. Circulation 2011;123:1974-1985